/Investor DB

Rock Springs Capital — 2022 Investments

3 investments dated 2022 · listed companies and verified rows first · show all

Avenge Bioavengebio.comJan 2022 · $45M

Linklist is a link-in-bio tool that lets brands consolidate their links and products on a single page, including a digital catalog, URL shortener, and QR code generator.

E-commerceMarketing TechSaaS

Co-investorsLongitude CapitalPappas CapitalPerceptive Xontogeny Venture

MOMA Therapeuticsmomatx.comin𝕏May 2022 · $150M

A drug discovery company staffed by scientists and industry specialists focused on developing pharmaceutical candidates.

Biotech

Timur Yusufzai(Founder)inAsit Parikh(Chief Executive Officer)in

Co-investorsLifeSci Venture PartnersNextech InvestThird Rock VenturesAlexandriaCasdin CapitalCreacion Ventures+4 more

Simcha Therapeuticssimchatx.cominJan 2022 · $40M

Simcha is a biotechnology company developing new cancer medicines based on immune biology research.

BiotechHealthtechNew Haven, US

Aaron Ring(Executive Officer, Director)inBeatrice McQueen(Chief Operating Officer)inSanuj Ravindran(Chief Executive Officer)Jeremy Barton(Chief Medical Director)Hirdesh Uppal(Senior Vice President Translational Research and Development Sciences)Joseph Catino(Executive Officer)

Co-investorsConnecticut InnovationsPfizer Venture InvestmentsSR One Capital ManagementAxial VCBiotechnology Value FundSamsara BioCapital

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.